US FDA accepts Orexigen Therapeutics’ NDA for obesity drug Contrave

US FDA accepts Orexigen Therapeutics’ NDA for obesity drug Contrave
US Food and Drug Administration (FDA) has accepted for filing Orexigen Therapeutics, Inc’s New Drug Application (NDA) for Contrave (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.

Read more on PharmaBiz